Utah Medical Products, Inc. Financials

Market Capitalization $212.8 Million as of Jan. 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	14.42
Forward PE
Price to Sales TTM	$4.82
Price to Book MRQ	$1.85
Enterprise to Revenue	2.92
Enterprise to EBITDA	5.95

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	33.39%
Operating Margin	34.24%
Return on Assets TTM	8.49%
Return on Equity TTM	13.33%

Income Statement

Revenue TTM	$49,044,000
Revenue per Share TTM	$13.53
Quarterly Revenue Growth	-9.40%
Gross Profit TTM	$30,038,000
EBITDA	$23,145,000
Net Income to Common TTM	$16,377,000
Diluted EPS TTM	$4.57
Quarterly Earnings Growth YoY	-6.10%

Balance Sheet

Total Cash MRQ	$93,808,000
Total Cash per Share MRQ	$26.14
Total Debt MRQ	$
Total Debt to Equity MRQ	0.22
Current Ratio MRQ	19.57
Book Value per Share MRQ	$35.60

Cash Flow

Operating Cash Flow TTM	$23,679,000
Levered Free Cash Flow TTM	$16,635,000

UTMD Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	3,589,010
Float Shares	3,149,841
Avg 10 Volume	29,360
Avg 30 Volume	None
Shares Short	88,831
Short Ratio	2.61
Short % of Shares	3.00%
% Held by Insiders	6.52%
% Held by Institutions	72.09%

Stock Price Summary

Beta	0.13
Fifty Two Week Low	$65.91
Fifty Two Week High	$100.59
Fifty Two Week Change	-37.81%
Day 50 MA	$69.55
Day 200 MA	$81.66

Dividends and Splits

Forward Annual Dividend Rate	$1.20
Forward Annual Dividend Yield	1.77%
Trailing Annual Dividend Rate	$1.19
Trailing Annual Dividend Yield	1.75%
Payout Ratio	25.93%
Dividend Date	2024-04-03
Ex Dividend Date	2024-03-14
Last Split Factor
Last Split Date